Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation

DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma

(2015) Corina A. Schmid et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

Uncoupling Malt1 Threshold Function from Paracaspase Activity Results in Destructive Autoimmune Inflammation

(2014) Andreas Gewies et al.   Cell Reports

Malt1-Induced Cleavage of Regnase-1 in CD4+ Helper T Cells Regulates Immune Activation

(2013) Takuya Uehata et al.   CELL

c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma

(2013) Vasiliki Leventaki et al.   HUMAN PATHOLOGY

Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials

(2013) Jennifer R. Brown   Current Hematologic Malignancy Reports

Human lymphoma mutations reveal CARD11 as the switch between self-antigen–induced B cell death or proliferation and autoantibody production

(2012) Yogesh S. Jeelall et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

(2011) Véronique Plantevin Krenitsky et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1

(2011) Jens Staal et al.   EMBO JOURNAL

Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory Domain

(2010) Rebecca L. Lamason et al.   BIOCHEMISTRY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma

(2010) Konstanze Pechloff et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic Activation of NF- B

(2010) L. M. Staudt   Cold Spring Harbor Perspectives in Biology

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Comprehending the complex connection between PKCβ, TAK1, and IKK in BCR signaling

(2009) Hisaaki Shinohara et al.   IMMUNOLOGICAL REVIEWS

Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells

(2009) Uta Ferch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125

(2009) Miao Wang et al.   JOURNAL OF PATHOLOGY

Casein kinase 1α governs antigen-receptor-induced NF-κB activation and human lymphoma cell survival

(2009) Nicolas Bidère et al.   NATURE

T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20

(2008) Beatrice Coornaert et al.   NATURE IMMUNOLOGY

The proteolytic activity of the paracaspase MALT1 is key in T cell activation

(2008) Fabien Rebeaud et al.   NATURE IMMUNOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE